These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 8562858

  • 1. Current treatment of BPH.
    Roylance P, Gibelin B, Espié J.
    Biomed Pharmacother; 1995; 49(7-8):332-8. PubMed ID: 8562858
    [Abstract] [Full Text] [Related]

  • 2. [Benign hypertrophy of the prostate: which treatment, for whom?].
    Schulman C.
    Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895
    [Abstract] [Full Text] [Related]

  • 3. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
    Agha AH, Roy JB, Culkin DJ, Lyon K.
    Adv Ther; 1995 Sep; 12(6):361-6. PubMed ID: 10163332
    [Abstract] [Full Text] [Related]

  • 4. Medical management of benign prostatic hyperplasia: a review.
    Magoha GA.
    East Afr Med J; 1996 Jul; 73(7):453-6. PubMed ID: 8918007
    [Abstract] [Full Text] [Related]

  • 5. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ, Miner M.
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [Abstract] [Full Text] [Related]

  • 6. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
    Keetch DW, Andriole GL, Ratliff TL, Catalona WJ.
    Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
    [Abstract] [Full Text] [Related]

  • 7. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).
    Vela-Navarrete R, Gonzalez-Enguita C, Garcia-Cardoso JV, Manzarbeitia F, Sarasa-Corral JL, Granizo JJ.
    BJU Int; 2005 Nov; 96(7):1045-8. PubMed ID: 16225526
    [Abstract] [Full Text] [Related]

  • 8. The American Urological Association symptom score in the evaluation of men with lower urinary tract symptoms: at 2 years of followup, does it work?
    Kaplan SA, Olsson CA, Te AE.
    J Urol; 1996 Jun; 155(6):1971-4. PubMed ID: 8618299
    [Abstract] [Full Text] [Related]

  • 9. [Current drug therapy of benign prostatic hyperplasia].
    Schmidbauer CP, Madersbacher S.
    Wien Med Wochenschr; 1996 Jun; 146(8):161-4. PubMed ID: 8767400
    [Abstract] [Full Text] [Related]

  • 10. Treatment and pharmacologic management of BPH in the context of common comorbidities.
    O'Leary MP.
    Am J Manag Care; 2006 Apr; 12(5 Suppl):S129-40. PubMed ID: 16613527
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Anwarul Islam AK, Kashem MA, Shameem IA, Kibria SA.
    Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
    [Abstract] [Full Text] [Related]

  • 12. 5alpha-reductase inhibitors/finasteride.
    Stoner E.
    Prostate Suppl; 1996 Aug; 6():82-7. PubMed ID: 8630236
    [Abstract] [Full Text] [Related]

  • 13. Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia.
    Magoha GA.
    East Afr Med J; 1998 May; 75(5):260-3. PubMed ID: 9746993
    [Abstract] [Full Text] [Related]

  • 14. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
    McDonald H, Hux M, Brisson M, Bernard L, Nickel JC.
    Can J Urol; 2004 Aug; 11(4):2327-40. PubMed ID: 15380054
    [Abstract] [Full Text] [Related]

  • 15. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
    Marberger M.
    Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
    [Abstract] [Full Text] [Related]

  • 16. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery.
    Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J, Emberton M.
    Eur Urol; 2004 May; 45(5):620-6; discussion 626-7. PubMed ID: 15082205
    [Abstract] [Full Text] [Related]

  • 17. [Finasteride (Proscar) for benign prostatic hypertrophy].
    Matzkin H, Chen J, Braf Z.
    Harefuah; 1993 Dec 15; 125(12):453-6, 496. PubMed ID: 7509305
    [Abstract] [Full Text] [Related]

  • 18. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA, McVary KT.
    Int J Impot Res; 2008 Dec 15; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [Abstract] [Full Text] [Related]

  • 19. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.
    Sarma AV, Jacobson DJ, McGree ME, Roberts RO, Lieber MM, Jacobsen SJ.
    J Urol; 2005 Jun 15; 173(6):2048-53. PubMed ID: 15879823
    [Abstract] [Full Text] [Related]

  • 20. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG.
    BJU Int; 2008 Mar 15; 101 Suppl 3():17-21. PubMed ID: 18307681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.